A 6-week, multicentre, randomised, double-blind, double-dummy, active-controlled, clinical safety study of lumiracoxib and rofecoxib in osteoarthritis patients

BMC Musculoskeletal Disorders

Volumn 9, Issue , 2008, Pages

  Stricker, Kirstin ^a   Yu, Sue ^a   Krammer, Gerhard ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; CALCIUM CARBONATE; LUMIRACOXIB; MAGNESIUM CARBONATE; PLACEBO; ROFECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DRUG DERIVATIVE; LACTONE; SULFONE;

ABDOMINAL PAIN; ADULT; AGED; ARM EDEMA; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DISEASE ACTIVITY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPHAGIA; EUROPE; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INFLUENZA; LEG EDEMA; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORNING DOSAGE; MULTICENTER STUDY; NAUSEA; OSTEOARTHRITIS; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PERIPHERAL SWELLING; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE; VAGINA BLEEDING; VOMITING; ARTHRALGIA; BLOOD PRESSURE; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; DRUG EFFECT; EDEMA; GASTROINTESTINAL TRACT; INCIDENCE; KIDNEY; LONGITUDINAL STUDY; MIDDLE AGED; PATHOPHYSIOLOGY;

AGED; ARTHRALGIA; BLOOD PRESSURE; CYCLOOXYGENASE 2 INHIBITORS; DICLOFENAC; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EDEMA; EUROPE; FEMALE; GASTROINTESTINAL TRACT; HUMANS; INCIDENCE; KIDNEY; LACTONES; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OSTEOARTHRITIS; SULFONES;

EID: 52249111393     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-9-118     Document Type: Article

References (36)

1. Burden of major musculoskeletal conditions. AD Woolf B Pfleger, Bull World Health Organ 2003 81 9 646 656 14710506
2. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 2000 43 9 1905 1915 10.1002/1529-0131(200009)43:9<1905::AID-ANR1>3.0.CO;2-P 11014340
3. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. L Laine, Gastroenterology 2001 120 3 594 606 10.1053/gast.2001.21907 11179238
4. NSAIDs and the gastrointestinal mucosa. MM Wolfe, Hosp Pract (Minneap) 1996 31 12 37 44 8969678
5. Nonsteroidal anti-inflammatory drugs and dyspepsia in the elderly. N Talley J Evans K Fleming W Harmsen A Zinmeister L Melton III, Dig Dis Sci 1995 40 1345 1350 10.1007/BF02065549 7781458
6. The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors. L Laine, Semin Arthritis Rheum 2002 32 3 Suppl 1 25 32 10.1053/sarh.2002.37217 12528071
7. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. G Singh DR Ramey D Morfeld H Shi HT Hatoum JF Fries, Arch Intern Med 1996 156 14 1530 1536 10.1001/archinte.156.14.1530 8687261
8. Epidemiology of NSAID induced gastrointestinal complications. G Singh G Triadafilopoulos, J Rheumatol Suppl 1999 56 18 24 10225536
9. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. JL Goldstein P Correa WW Zhao AM Burr RC Hubbard KM Verburg GS Geis, Am J Gastroenterol 2001 96 4 1019 1027 10.1111/j.1572-0241.2001.03740.x 11316141
10. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. MJ Langman DM Jensen DJ Watson SE Harper PL Zhao H Quan JA Bolognese TJ Simon, Jama 1999 282 20 1929 1933 10.1001/jama.282.20.1929 10580458
11. Merck & Company, Inc. Merck announces voluntary worldwide withdrawal of VIOXX. http://www.vioxx.com/vioxx/documents/english/vioxx_press_release.pdf
12. FDA, http://www.fda.gov/bbs/topics/news/2005/NEW01171.html
13. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. PM Kearney C Baigent J Godwin H Halls JR Emberson C Patrono, Bmj 2006 332 7553 1302 1308 16740558 10.1136/bmj.332.7553.1302
14. Risk of acute myocardial infarction with nonselective non-steroidal anti-inflammatory drugs: a meta-analysis. G Singh O Wu P Langhorne R Madhok, Arthritis Res Ther 2006 8 5 R153 16995929 10.1186/ar2047
15. Analgesic efficacy of single oral doses of lumiracoxib and ibuprofen in patients with postoperative dental pain. K Zelenakas JR Fricke Jr S Jayawardene D Kellstein, Int J Clin Pract 2004 58 3 251 256 10.1111/j.1368-5031.2004.00156.x 15117091
16. Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of gout. RE Willburger E Mysler J Derbot T Jung HJ Thurston A Kreiss S Litschig G Krammer GA Tate, Rheumatology (Oxford) 2007 46 7 1126 1132 10.1093/rheumatology/kem090 17478464
17. The post-operative analgesic efficacy and tolerability of lumiracoxib compared with placebo and naproxen after total knee or hip arthroplasty. VW Chan AJ Clark JC Davis RS Wolf D Kellstein S Jayawardene, Acta Anaesthesiol Scand 2005 49 10 1491 1500 10.1111/j.1399-6576.2005.00782.x 16223396
18. Lumiracoxib 400 mg once daily is comparable to naproxen 500 mg twice daily for treatment of acute muscular pain following soft tissue injury [abstract]. C Kyle J Zachariah M Kasangra C Andrews G Ellis H Kinch, Ann Rheum Dis 2006 65 241
19. Lumiracoxib is effective and well tolerated in the long-term treatment of knee osteoarthritis. K Pavelka O Zamani R Alten S Yu S Litschig VS Sloan, Ann Rheum Dis 2005 64 353
20. Retention on treatment with lumiracoxib in patients with osteoarthritis [abstract]. R Fleischmann H Tannenbaum NP Patel M Notter P Sallstig J-Y Reginster, Osteoarthritis Cartilage 2006 14 S165 10.1016/S1063-4584(07)60750-X
21. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. TJ Schnitzer GR Burmester E Mysler MC Hochberg M Doherty E Ehrsam X Gitton G Krammer B Mellein P Matchaba, Lancet 2004 364 9435 665 674 10.1016/S0140-6736(04)16893-1 15325831
22. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. ME Farkouh H Kirshner RA Harrington S Ruland FW Verheugt TJ Schnitzer GR Burmester E Mysler MC Hochberg M Doherty, Lancet 2004 364 9435 675 684 10.1016/S0140-6736(04)16894-3 15325832
23. Significant early reduction of ulcer complications with lumiracoxib compared with naproxen at Day 8 of treatment in TARGET. CJ Hawkey W Weinstein WE Smalley D Richard G Krammer P Sallstig B Mellein P Matchaba, DDW Washington DC 2007
24. Lumiracoxib provides superior blood pressure profile compared to NSAIDs after 4 weeks of treatment. ME Farkouh FWK Verheugt H Kirshner S Ruland P Sallstig K Stricker G Krammer B Mellein X Gitton P Matchaba, Poster No 1692, ACR/ARHP 2006 Annual Scientific Meeting, Washington
25. Cohort study of hepatotoxicity associated with nimesulide and other non-steroidal anti-inflammatory drugs. G Traversa C Bianchi R Da Cas I Abraha F Menniti-Ippolito M Venegoni, BMJ 2003 327 18 22 12842950 10.1136/bmj.327.7405.18
26. Comparison of the gastrointestinal safety of lumiracoxib with traditional NSAIDs early after the initiation of treatment: findings from the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET). CJ Hawkey WM Weinstein K Stricker V Murphy D Richard G Krammer R Rebuli, Aliment Pharmacol Ther 2008 27 838 845 18221410
27. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. AG Johnson TV Nguyen RO Day, Ann Intern Med 1994 121 4 289 300 8037411
28. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. TJ Aw SJ Haas D Liew H Krum, Arch Intern Med 2005 165 5 490 496 10.1001/archinte.165.5.IOI50013 15710786
29. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. CP Cannon SP Curtis GA FitzGerald H Krum A Kaur JA Bolognese AS Reicin C Bombardier ME Weinblatt D van der Heijde, Lancet 2006 368 9549 1771 1781 10.1016/S0140-6736(06)69666-9 17113426
30. Consequences of increased systolic blood pressure in patients with osteoarthritis and rheumatoid arthritis. G Singh JD Miller DM Huse D Pettitt RB D'Agostino MW Russell, J Rheumatol 2003 30 4 714 719 12672188
31. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. S Lewington R Clarke N Qizilbash R Peto R Collins, Lancet 2002 360 9349 1903 1913 10.1016/S0140-6736(02)11911-8 12493255
32. Treating osteoarthritis with cyclooxygenase-2-specific inhibitors: what are the benefits of avoiding blood pressure destabilization? SA Grover L Coupal H Zowall, Hypertension 2005 45 1 92 97 15545508
33. Improved blood pressure control in hypertensive patients with osteoarthritis treated with lumiracoxib: randomized controlled trial of lumiracoxib versus ibuprofen [abstract]. TM MacDonald D Richard T Lheritier G Krammer, J Clin Hypertens 2007 9 A91 A92
34. Blood pressure profile of lumiracoxib is similar to placebo in arthritis patients. A Whitehead M Simmonds B Mellein T Friede X Gitton P Sallstig, Osteoarthritis Cartilage 2006 14 S168 S169 10.1016/S1063-4584(07)60757-2
35. Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET) of lumiracoxib versus NSAIDs: incidence of de-novo hypertension and oedema. J Zacher P Hasler E Martín Mola B Mellein G Krammer X Gitton, Ann Rheum Dis 2005 64 483
36. FDA, 10 http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b2_06_cardio. pdf